Drugs-Forum  
Home Wiki Studies Forum Groups Blog Video Images News
Go Back   Drugs Forum > Wiki Articles > Drug Law Articles
Mark Forums Read
Register Tags

Notices

Drug Law Articles This forum hosts all Drug Law Wiki entries

Drug Laws in Australia

This article gives information on the scheduling of drugs, poisons and medicines in Australia. It draws information from the TGA (Therapeutic Goods Administration) under the Australian Government Department of Health and Ageing. Any changes to the scheduling of drugs is made by The Standard for the Uniform Scheduling of Medicines and Poisons (SUSMP) and the scheduling process is constantly under review and, therefore, any content in this article may be subject to change at any time.
Drugs-Forum.com accepts no responsibility for any legal or physical harm that may arise as a consequence of following the information found in this article. Lists of scheduled drugs drawn from STANDARD FOR THE UNIFORM SCHEDULING OF MEDICINES AND POISONS, written by Anthony Gill, are to be used for the sole purpose of information within the non-profit organisation Drugs-Forum.com.


Contents


[top]Scheduled Drugs

[top]Schedule 1 - Not currently in use


This schedule is a defunct schedule and is left intentionally blank. It is no longer relevant under current Australian drug laws.

[top]Schedule 2 - Pharmacy Medicine


This schedule is for ailments or conditions that do not require medical attention and can easily be diagnosed by the consumer. These drugs may be found in supermarkets or on the shelf at pharmacies. These medications may include such drugs as aspirin, paracetamol (acetaminophen), ibuprofen and various natural vitamin supplements.

[top]Schedule 3 - Pharmacist Only Medicine


This schedule is for pharmacist only medicines which are kept behind the counter and must be dispensed with the permission of the pharmacist, but do NOT require a doctor's prescription. Particular examples, apart from the listed examples, would include codeine and pseudoephidrine. The pharmacist may require identification such as a drivers license to dispense these medications. Codeine is dispensed as a pharmacy only medicine at the highest amount of 15mg per tablet when combined with caffeine and 500mg acetaminophen. Pseudoephidrine can be dispensed by the pharmacist at the pharmacists discretion, but may be refused if sufficient identification cannot be produced, or if the pharmacist so decides.

[top]Schedule 4 - Prescription Only Medicine


Prescription only medicines can only be obtained from a pharmacy when holding a valid prescription written by a medical practitioner. This schedule also contains drugs for veterinary purposes for animals. Prescriptions for schedule 4 drugs may also be dispensed at hospital pharmacies with the consent of the doctor in charge. Some medications in schedule 4 will not be prescribed by certain doctors or medical centres. Primary examples of some medications that certain doctors refuse to prescribe are benzodazepines such as diazepam, nitrazepam, temazepam and alprazolam. It is also common to see notices in medical centres explaining that opiates will not be prescribed. Certain opiates in schedule 4 that some medical practitioners will not prescribe are codeine at levels of 30mg per tablet or higher. This is due to the potential for abuse and addiction that some doctors consider this drugs to have.

[top]Schedules 5-7 - Poisons


Schedules 5-7 are particular substances that are considered to be poisonous to humans.
Schedule 5 is for substances that are to be treated with caution and will labelled as such. They must have the expression POISON, NOT TO BE TAKEN or NOT TO BE USED AS A FOOD CONTAINER. Examples may include methylated spirits, kerosene, turpentine and petrol.
Schedule 6 is for substances considered dangerous. They will have labels appropriate to the poisons in schedule 5 but will include substances such as alkaline salts, eucalyptus oil or hydrocarbons when packed as kerosene, lamp oil or turpentine.
Schedule 7 is for substances considered to be extremely dangerous. These substances must have authority to be possessed by the appropriate government body. These substances may include arsenic, cyanide, hydrocyanic acid, strychnine and thallium.

[top]Schedule 8 - Controlled Drugs


Schedule 8 is for any substance that is considered addictive or that has the potential for abuse. Doctors must have a schedule 8 permit in order to prescribe these medications. It is also illegal to be in possession of these drugs if you are not the person who has been prescribed the drug. It may be necessary to show identification if these drugs are being transported. Examples of these drugs would be amphetamines, most barbiturates, cocaine, codeine as a single ingredient, fentanyl, methadone, morphine and oxycodone. As with schedule 4, many medical centres will display signs indicating that certain schedule 8 drugs will not be prescribed. Particular drugs that will often not be prescribed are endone (immediate release oxycodone), oxycontin and morphine sulfate as an oral preparation. Often certain medical clinics will not have doctors with a schedule 8 permit, which makes the prescribing of these drugs illegal.
Interestingly, cocaine is classified as a schedule 8 drug because of it's use in certain veterinary and pharmaceutical preparations. However it is illegal in any other circumstance and is generally considered as an outlawed drug.

[top]Schedule 9 - Prohibited Substance


Schedule 9 substances are drugs that are prohibited in Australia except for the purposes of research. If a schedule 9 drug is used for research, a permit must be obtained to do so. Otherwise these substances are strictly prohibited. Some drugs in this schedule would include cannabis, heroin, LSD and MDMA. Cocaine is not in schedule 9 but in schedule 8 due to the fact that it is used in some dental and pharmacy preparations. It is not, however, legal to be in possession of cocaine outside of those specific environments.
Cannabis is an illicit drug in Australia, but some states and territories have decriminalised it. This means that in certain states and territories, namely South Australia, Australian Capital Territory and Northern Territory, possession of small amounts of cannabis will result in a civil fine at the minimum amount of $50, similar to the severity of a speeding fine. Therefore in these states and territories there is no civil charge for cannabis possession. In the other states, namely New South Wales, Queensland, Victoria, Western Australia and Tasmania, the possession of cannabis is a criminal offense and could result in a jail sentence and a criminal record. However it is unlikely that someone carrying a small amount of cannabis in these states would receive a criminal conviction.

[top]Lists of Scheduled Drugs

[top]Schedule 2


ACETIC ACID (excluding its salts and derivatives) and preparations containing
more than 80 per cent of acetic acid (CH3COOH) for therapeutic use.
AMOROLFINE in preparations for topical use except in preparations for the treatment of tinea pedis.
ANTAZOLINE in eye drops.
ASPIRIN except:(a)when included in Schedule 4, 5 or 6.
BENZYDAMINE in preparations for topical use, except in preparations for dermal use.
BEPHENIUM SALTS.
BIFONAZOLE in preparations for dermal use except:(a)in preparations containing 1 per cent or less of bifonazole for the treatment of the scalp; or (b)in preparations for the treatment of tinea pedis.
BUDESONIDE in aqueous nasal sprays delivering 50 micrograms or less of budesonide per actuation when the maximum recommended daily dose is no greater than 400 micrograms and when packed in a primary pack containing 200 actuations or less, for the prophylaxis or treatment of allergic rhinitis for up to 6 months in adults and children 12 years of age and over.
CHLOROFORM in preparations for therapeutic use except:(a)when included in Schedule 4; or (b)in preparations containing 0.5 per cent or less of chloroform.
CODEINE in preparations for the treatment of coughs and colds when:(a)not combined with any other opiate substance;(b)compounded with one or more other therapeutically active substances, of which at least one is phenylephrine and not more than one is an analgesic substance:(i)in divided preparations containing 10 mg or less of codeine per dosage unit; or (ii)in undivided preparations containing 0.25 per cent or less of codeine (c)labelled with a recommended daily dose not exceeding 60 mg of codeine; and (d)in packs containing not more than 6 days' supply at the maximum dose recommended on the label.
DEXCHLORPHENIRAMINE when combined with one or more other therapeutically active substances in oral preparations when:(a)at least one of the other therapeutically active substances is a sympathomimetic decongestant; or(b)in a day-night pack containing dexchlorpheniramine in the bed-time dose where the day and night doses are in the same immediate container or immediate wrapper,except in preparations for the treatment of children under 2 years of age.
ECONAZOLE for human use in dermal preparations except in preparations for the treatment of tinea pedis.
ETAFEDRINE.
ETHER for therapeutic use except:(a)when included in Schedule 4; or(b)in preparations containing 10 per cent or less of ether.
FLUTICASONE in aqueous nasal sprays delivering 50 micrograms or less of fluticasone per actuation when the maximum recommended daily dose is no greater than 400 micrograms and when packed in a primary pack containing 200 actuations or less, for the prophylaxis or treatment of allergic rhinitis for up to 6 months in adults and children 12 years of age and over.
GUAIPHENESIN in a modified release dosage form of 1200 mg or less of guaiphenesin with a recommended daily dose of 2400 mg or less when not labelled for the treatment of children under 12 years of age.
GELSEMIUM SEMPERVIRENS.
GLUTARALDEHYDE for human therapeutic use.
HYOSCINE BUTYLBROMIDE as the only therapeutically active substance, in divided preparations for oral use, containing 20 mg or less of hyoscine butylbromide per dosage unit in a pack containing 200 mg or less of hyoscine butylbromide.
IPRATROPIUM in preparations for nasal use.
IRON COMPOUNDS (excluding iron oxides when present as an excipient, in divided preparations containing 10 mg or less of total iron oxides per dosage unit or in undivided preparations containing 1 per cent or less of total iron oxides) for human internal use except:(a)when included in Schedule 4; or(b) when labelled with a recommended daily dose of 24 mg or less of iron:(i)in undivided preparations supplied in packs each containing 750 mg or less of iron; or(ii) in divided preparations:(A)containing more than 5 mg of iron per dosage unit in packs each containing 750 mg or less of iron; or(B)containing 5 mg or less of iron per dosage unit.
ISOCONAZOLE for human use in dermal preparations.
ISOPROPAMIDE in preparations for dermal use containing 2 per cent or less of isopropamide.
LINDANE in preparations for human external therapeutic use containing 2 per cent or less of lindane.
LOBELIA INFLATA except for smoking or burning.
LOBELINE except in preparations for smoking or burning.
LODOXAMIDE in preparations for ophthalmic use.
LOPERAMIDE in divided preparations for oral use in packs of 20 dosage units or less except in preparations containing 2 mg or less of loperamide per dosage unit, in a primary pack containing 8 dosage units or less.
LORATADINE in preparations for oral use.
MEBENDAZOLE for human therapeutic use.
MECLOZINE in primary packs containing 12 or less tablets or capsules of meclozine for the prevention or treatment of motion sickness, except in preparations for the treatment of children under 2 years of age.
MEFENAMIC ACID in divided preparations for oral use in packs of 30 or less dosage units for the treatment of dysmenorrhoea.
MEPYRAMINE for dermal use.
MERCUROCHROME in preparations for external use containing 2 per cent or less of mercurochrome except when included in Schedule 6.
MERCURY for external use in preparations containing 0.5 per cent or less of mercury.
METHOXAMINE in preparations for external use except in preparations containing 1 per cent or less of methoxamine.
METHOXYPHENAMINE .
METHYLEPHEDRINE.
MICONAZOLE for human use in dermal preparations and for application to the nails except in preparations for the treatment of tinea pedis.
MINOXIDIL in preparations for dermal use containing 5 per cent or less of minoxidil.
MOMETASONE in aqueous nasal sprays delivering 50 micrograms or less of mometasone per actuation when the maximum recommended daily dose is no greater than 200 micrograms for the prophylaxis or treatment of allergic rhinitis for up to six months in adults and children 12 years of age and over.
NAPHAZOLINE.
NAPROXEN in divided preparations containing 250 mg or less of naproxen per dosage unit in packs of 30 or less dosage units.
NICLOSAMIDE for human therapeutic use.
NIZATIDINE when sold in the manufacturer’s original pack containing not more than 14 days' supply.
NOSCAPINE.
NYSTATIN in dermal preparations.
OXETACAINE (oxethazaine) in preparations for internal use.
OXICONAZOLE for dermal use except in preparations for the treatment of tinea pedis.
OXYMETAZOLINE.
PAPAVERINE except when included in Schedule 4.
PARACETAMOL for therapeutic use except:(a)when included in Schedule 4;(b)in individually wrapped powders or sachets of granules each containing 1000 mg or less of paracetamol as the only therapeutically active constituent (other than phenylephrine and/or guaiphenesinor when combined with effervescent agents) when:(i)enclosed in a primary pack that contains not more than 12 such powders or sachets of granules;(ii) compliant with the requirements of the Required Advisory Statements for Medicine Labels;(iii)not labelled for the treatment of children 6 years of age or less; and(iv)not labelled for the treatment of children under 12 years of age when combined with phenylephrine and/or guaiphenesin; or(c)in tablets or capsules each containing 500 mg or less of paracetamol as the only therapeutically active constituent (other than phenylephrine and/or guaiphenesin or when combined with effervescent agents) when:(i) packed in blister or strip packaging or in a container with a child-resistant closure;(ii)in a primary pack containing not more than 25 tablets or capsules;(iii)compliant with the requirements of the Required Advisory Statements for Medicine Labels;(iv)not labelled for the treatment of children 6 years of age or less; and(v) not labelled for the treatment of children under 12 years of age when combined with phenylephrine and/or guaiphenesin.
PHEDRAZINE.
PHENAZONE for human external use.
PROCYCLIDINE in preparations containing 5 per cent or less of procyclidine for dermal use.
PROPAMIDINE for ophthalmic use.
PYRANTEL for human therapeutic use.
PYRETHRINS, naturally occurring, being pyrethrolone, cinerolone or jasmolone esters of chrysanthemic or pyrethric acids, for human therapeutic use in preparations containing more than 10 per cent of such substances.
PYRITHIONE ZINC for human therapeutic use, except in preparations for the treatment of the scalp containing 2 per cent or less of pyrithione zinc when compliant with the requirements of the Required Advisory Statements for Medicine Labels.
RANITIDINE in preparations supplied in the manufacturer’s original pack containing not more than 14 days' supply except in divided preparations for oral use containing 150 mg or less of ranitidine per dosage unit in the manufacturer’s original pack containing not more than 14 dosage units.
SALICYLAMIDE except when included in Schedule 4.
SODIUM CROMOGLYCATE in preparations for nasal or ophthalmic use.
SODIUM NITRITE for therapeutic use (excluding when present as an excipient).
SQUILL except in preparations containing 1 per cent or less of squill.
SULCONAZOLE in preparations for dermal use.
TERBINAFINE for dermal use except in preparations for the treatment of tinea pedis.
TETRACHLOROETHYLENE for human therapeutic use.
TETRAHYDROZOLINE.
THIABENDAZOLE for human therapeutic use.
TIOCONAZOLE in preparations for dermal use except in preparations for the treatment of tinea pedis.
TRAMAZOLINE.
TRIAMCINOLONE in aqueous nasal sprays delivering 55 micrograms or less of triamcinolone per actuation when the maximum recommended daily dose is no greater than 220 micrograms, for prophylaxis or treatment of allergic rhinitis for up to 6 months in adults and children 12 years of age and over.
TUAMINOHEPTANE.
TYMAZOLINE.
XYLOMETAZOLINE.
ZINC CHLORIDE for human dermal use except in preparations containing 5 per cent or less of zinc chloride.

[top]Schedule 3


ADRENALINE in preparations containing 1 per cent or less of adrenaline except in preparations containing 0.02 per cent or less of adrenaline.
ALCLOMETASONE as the only therapeutically active substance in preparations for dermal use containing 0.05 per cent or less of alclometasone in packs containing 30 g or less of the preparation.
AMINOPHYLLINE in liquid oral preparations containing 2 per cent or less of aminophylline.
AZATADINE in oral preparations.
BUCLIZINE in oral preparations.
BUTOCONAZOLE in preparations for vaginal use.
CHLORAMPHENICOL for ophthalmic use only.
CIMETIDINE in a primary pack containing not more than 14 days' supply.
CLEMASTINE in preparations for oral use.
CLOBETASONE (clobetasone-17-butyrate) as the only therapeutically active substance in preparations for dermal use containing 0.05 per cent or less of clobetasone in packs containing 30 g or less of the preparation.
CLOTRIMAZOLE in preparations for vaginal use.
CODEINE when:(a)not combined with any other opiate substance;(b)compounded with one or more other therapeutically active substances, of which not more than one is an analgesic substance:(i)in divided preparations containing 12 mg or less of codeine per dosage unit; or(ii)in undivided preparations containing 0.25 per cent or less of codeine;(c)labelled with a recommended daily dose not exceeding 100 mg of codeine; and(d)in packs containing not more than 5 days' of supply at the maximum dose recommended on the label,
except when included in Schedule 2.
*Codeine is now available in schedule 3 in 15mg tablets when prepared with 500mg acetaminophen.
CYCLIZINE in preparations for oral use.
CYPROHEPTADINE in oral preparations.
DICLOFENAC in divided preparations for oral use containing 25 mg or less of diclofenacper dosage unit in a pack containing 30 or less dosage units except when included in Schedule 2.
DIHYDROCODEINE when compounded with one or more other therapeutically active substances:(a)in divided preparations containing 10 mg or less per dosage unit and with a recommended dose not exceeding 15 mg of dihydrocodeine; or(b)in undivided preparations containing 0.25 per cent or less of dihydrocodeine with a recommended dose not exceeding 15 mg of dihydrocodeine,except when included in Schedule 2.
DI-IODOHYDROXYQUINOLINE (iodoquinol) for vaginal use.
DIMENHYDRINATE in oral preparations except when included in Schedule 2.
DIMETHINDENE in oral preparations.
DIPHENOXYLATE in packs of 8 or less dosage units, each dosage unit containing 2.5 mg or less of diphenoxylate and a quantity of atropine sulfate equivalent to at least 1 per cent of the dose of diphenoxylate.
DITHRANOL for therapeutic use.
ECONAZOLE in preparations for vaginal use.
ERYTHRITYL TETRANITRATE for therapeutic use.
FAMCICLOVIR for oral use, in divided preparations containing a total dose of 1500 mg or less of famciclovir for the treatment of herpes labialis (cold sores).
FLAVOXATE.
FLUCONAZOLE in single-dose oral preparations containing 150 mg or less of fluconazole for the treatment of vaginal candidiasis.
IBUPROFEN in divided preparations, each containing 400 mg or less of ibuprofen in a primary pack containing not more than 50 dosage units when labelled:(a)with a recommended daily dose of 1200 mg or less of ibuprofen; and(b)not for the treatment of children under 12 years of age,except when included in or expressly excluded from Schedule 2.
INOSITOL NICOTINATE.
ISOCONAZOLE in preparations for vaginal use.
ISOSORBIDE DINITRATE in oral preparations containing 10 mg or less of isosorbide dinitrate per dosage unit.
KETOPROFEN in divided preparations for oral use containing 25 mg or less of ketoprofen per dosage unit in a pack containing 30 or less dosage units.
LANSOPRAZOLE in oral preparations containing 15 mg or less of lansoprazole per dosage unit for the relief of heartburn and other symptoms of gastro-oesophageal reflux disease, in packs containing not more than 14 days' supply.
LEVONORGESTREL for emergency post-coital contraception.
MACROGOLS in preparations for oral use for bowel cleansing prior to diagnostic, medical or surgical procedures.
MAGNESIUM SULFATE for human therapeutic use in divided oral preparations except when containing 1.5 g or less of magnesium sulfate per recommended daily dose.
MALATHION in preparations for human external use except in preparations containing 2 per cent or less of malathion.
MANNITYL HEXANITRATE for therapeutic use.
MEPYRAMINE in oral preparations.
METHDILAZINE in oral preparations.
METOCLOPRAMIDE when combined with paracetamol in divided preparations, packed and labelled only for the treatment of nausea associated with migraine, in packs containing not more than 10 dosage units.
NICOTINIC ACID for human therapeutic use in divided preparations containing 250 mg or less of nicotinic acid per dosage unit except:(a)in preparations containing 100 mg or less of nicotinic acid per dosage unit; or(b) nicotinamide.
NICOTINYL ALCOHOL except in preparations containing 100 mg or less of nicotinyl alcohol per dosage unit.
NYSTATIN in preparations for topical use except when included in Schedule 2.
OMEPRAZOLE in oral preparations containing 20 mg or less of omeprazole per dosage unit for the relief of heartburn and other gastro-oesophageal reflux disease, in packs containing not more than 14 days' supply.
ORLISTAT in oral preparations for weight-control purposes containing 120 mg or less of orlistat per dosage unit.
OXICONAZOLE in preparations for vaginal use.
PANTOPRAZOLE in oral preparations containing 20 mg or less of pantoprazole per dosage unit for the relief of heartburn and other symptoms of gastro-oesophageal reflux disease, in packs containing not more than 14 days' supply.
PARACETAMOL when combined with ibuprofen in a primary pack containing 30 dosage units or less.
PODOPHYLLOTOXIN in preparations containing 1 per cent or less of podophyllotoxin for human use for the treatment of warts other than anogenital warts except when included in Schedule 2.
PODOPHYLLUM EMODI (podophyllin) in preparations containing 20 per cent or less of podophyllin for human use for the treatment of warts other than anogenital warts except when included in Schedule 2.
PODOPHYLLUM PELTATUM (podophyllin) in preparations containing 20 per cent or less of podophyllin for human use for the treatment of warts other than anogenital warts except when included in Schedule 2.
PROCHLORPERAZINE in divided preparations for oral use in packs containing not more than 10 dosage units for the treatment of nausea associated with migraine.
PSEUDOEPHEDRINE (other than preparations for stimulant, appetite suppression or weight-control purposes) when supplied in a primary pack:(a)in liquid preparations containing 800 mg or less of pseudoephedrine hydrochloride (or its equivalent); or(b)in other preparations containing 720 mg or less of pseudoephedrine hydrochloride (or its equivalent).*Drivers licence or sufficient ID may be required by the pharmacist.
RABEPRAZOLE in oral preparations containing 10 mg or less of rabeprazole per dosage unit for the relief of heartburn and other symptoms of gastro-oesophageal reflux disease, in packs containing not more than 14 days' supply.
SALICYLIC ACID in preparations for dermal use except in preparations containing 40 per cent or less of salicylic acid.
SANTONIN.
SODIUM PHOSPHATE in preparations for oral use for bowel cleansing prior to diagnostic medical and surgical procedures.
SODIUM PICOSULFATE in preparations for oral use for bowel cleansing prior to diagnostic medical or surgical procedures.
SULFACETAMIDE in preparations for ophthalmic use containing 10 per cent or less of sulfacetamide.
THEOPHYLLINE in liquid oral preparations containing 2 per cent or less of theophylline.
TIOCONAZOLE in preparations for vaginal use.
TRIAMCINOLONE for buccal use in preparations containing 0.1 per cent or less of triamcinolone in a pack of 5 g or less.

[top]Schedule 4


ABACAVIR.
ABATACEPT.
ABCIXIMAB.
ACAMPROSATE CALCIUM.
ACARBOSE.
ACEBUTOLOL.
ACEPROMAZINE.
ACETANILIDE and alkyl acetanilides (excluding when present as an excipient) for human therapeutic use.
ACETARSOL.
ACETAZOLAMIDE.
ACETOHEXAMIDE.
ACETYL ISOVALERYLTYLOSIN.
ACETYLCARBROMAL.
ACETYLCHOLINE.
ACETYLDIGITOXIN.
ACETYLMETHYLDIMETHYLOXIMIDOPHENYLHYDRAZINE.
ACETYLSTROPHANTHIDIN.
ACICLOVIR except in preparations containing 5 per cent or less of aciclovir for the treatment of herpes labialis in packs containing 10 g or less.
ACIPIMOX.
ACOKANTHERA OUABAIO.
ACOKANTHERA SCHIMPERI.
ACRIVASTINE.ADALIMUMAB.
ADAPALENE.
ADEFOVIR.
ADENOSINE for human therapeutic use in preparations for injection.
ADIPHENINE.
ADONIS VERNALIS.
ADRAFINIL.
ADRENALINE except:(a)when included in Schedule 3; or (b)in preparations containing 0.02 per cent or less of adrenaline.
ADRENOCORTICAL HORMONES except when separately specified in these Schedules.
AFAMELANOTIDE.
AFLIBERCEPT.
AGALSIDASE.
AGLEPRISTONE.
AGOMELATINE.
ALATROFLOXACIN MESYLATE.
ALCLOFENAC.
ALCLOMETASONE except when included in Schedule 3.
ALCURONIUM.
ALDESLEUKIN.
ALDOSTERONE.
ALEMTUZUMAB.ALENDRONIC ACID.
ALFACALCIDOL.
ALFUZOSIN.
ALGLUCERASE.
ALGLUCOSIDASE.
ALISKIREN.
ALLERGENS.
ALLOPURINOL.
ALLYLOESTRENOL.
ALOSETRON.
ALPHA1-PROTEINASE INHIBITOR (HUMAN).
ALPHADOLONE.
ALPHAXALONE.
ALPRAZOLAM.
ALPRENOLOL.
ALPROSTADIL.
ALSEROXYLON.
ALTEPLASE.
ALTRENOGEST.
ALTRETAMINE (hexamethylmelamine).
AMANTADINE.
AMBENONIUM CHLORIDE.
AMBUCETAMIDE.
AMBUTONIUM BROMIDE.
AMCINONIDE.
AMIFOSTINE.
AMIKACIN.
AMILORIDE.
AMINOCAPROIC ACID.
AMINOGLUTETHIMIDE.
5-AMINOLEVULINIC ACID.
AMINOMETRADINE.
AMINOPHYLLINE except when included in Schedule3.
AMINOPTERIN.
4-AMINOPYRIDINE for therapeutic use.
AMINOREX.
AMINOSALICYLIC ACID.
AMITRIPTYLINE.
AMLODIPINE.
AMMI VISNAGA.
AMMONIUM BROMIDE for therapeutic use.
AMODIAQUINE.
AMOXAPINE.
AMOXYCILLIN.
AMPHOMYCIN.
AMPHOTERICIN.
AMPICILLIN.
AMPRENAVIR.
AMRINONE.
AMSACRINE.
AMYL NITRITE.
AMYLOBARBITONE when packed and labelled for injection.
AMYLOCAINE.
ANAGRELIDE.
ANAKINRA.
ANASTROZOLE.
ANCESTIM.
ANCROD and its immunoglobulin antidote.
ANECORTAVE.
ANTIGENS for human therapeutic use except when separately specified in this Schedule.
ANTIHISTAMINES except:(a)when included in Schedule 2 or 3; or(b)when separately specified in this Schedule.
ANTIMONY for therapeutic use except when separately specified in these Schedules.
ANTISERA (immunosera) for human use by injection except when separately specified in these Schedules.
APIXABAN.
APOCYNUM spp.
APOMORPHINE.
APRACLONIDINE.
APRAMYCIN.
APREPITANT.
APRONAL.
APROTININ.
ARECOLINE.
ARIPIPRAZOLE.
ARSENIC for human therapeutic use except when separately specified in these Schedules.
ARTEMETHER.
ARTICAINE.
ASENAPINE.
ASPIRIN:(a) when combined with caffeine, paracetamol or salicylamide or any derivative of these substances; or(b)for injection.
ASTEMIZOLE.
ATAZANAVIR.
ATENOLOL.
ATIPAMEZOLE.
ATOMOXETINE.
ATORVASTATIN.
ATOSIBAN.
ATOVAQUONE.
ATRACURIUM BESYLATE.
ATROPA BELLADONNA (belladonna) except when included in Schedule 2.
ATROPINE except when included in Schedule 2.
ATROPINE METHONITRATE.
AURANOFIN.
AUROTHIOMALATE SODIUM.
AZATADINE except when included in Schedule 3.
AZATHIOPRINE.
AZELASTINE except when included in Schedule 2.
AZITHROMYCIN.
AZLOCILLIN.
AZTREONAM.
BACAMPICILLIN.
BACITRACIN.
BACLOFEN.
BALSALAZIDE.
BAMBUTEROL.
BAMETHAN.
BAMIPINE.
BARBITURATES except when separately specified in these Schedules.
BASILIXIMAB.
BAZEDOXIFENE.
BECAPLERMIN.
BECLAMIDE.
BECLOMETHASONE except when included in Schedule 2.
BELATACEPT.
BELIMUMAB.
BEMEGRIDE.
BENACTYZINE.
BENAZEPRIL.
BENDROFLUAZIDE.
BENETHAMINE PENICILLIN.
BENORYLATE.
BENOXAPROFEN.
BENPERIDOL.
BENSERAZIDE.
BENZATHINE PENICILLIN.
BENZHEXOL.
BENZILONIUM.
BENZODIAZEPINE derivatives except when separately specified in these Schedules.
BENZPHETAMINE.
BENZTHIAZIDE.
BENZTROPINE (benzatropine).
BENZYLPENICILLIN.
BEPRIDIL.
BERACTANT.
BETAHISTINE.
BETAMETHASONE.
BETAXOLOL.
BETHANECHOL CHLORIDE.
BETHANIDINE.
BEVACIZUMAB.
BEVANTOLOL.
BEZAFIBRATE.
BICALUTAMIDE.
BIPERIDEN.
BISMUTH COMPOUNDS for human therapeutic use, except bismuth formic iodide or bismuth subiodide in dusting powders containing 3 per cent or less of bismuth.
BISOPROLOL.
BIVALIRUDIN.
BLEOMYCIN.
BOTULINUM TOXINS for human use except when separately specified in
these Schedules.
BRETYLIUM TOSYLATE.
BRIMONIDINE.
BRINZOLAMIDE.
BROMAZEPAM.
BROMIDES, inorganic, for therapeutic use except when separately specified in
these Schedules.
BROMOCRIPTINE.
BROMOFORM for therapeutic use.
BROMPHENIRAMINE except when included in Schedule2 or 3.
BROMVALETONE.
BRUGMANSIA spp.
BUCLIZINE except when included in Schedule3.
BUDESONIDE except when included in Schedule 2.
BUPHENINE.
BUPIVACAINE.
BUPROPION.
BUSERELIN.
BUSPIRONE.
BUSULPHAN.
BUTACAINE.
BUTOCONAZOLE except when included in Schedule 3.
BUTRACONAZOLE.
BUTYL AMINOBENZOATE except in dermal preparations containing 2 per cent or less of total local anaesthetic substances.
BUTYLCHLORAL HYDRATE.
BUTYL NITRITE.
CABAZITAXEL.
CABERGOLINE.
CADMIUM COMPOUNDS for human therapeutic use.
CALCIPOTRIOL.
CALCITONIN.
CALCITRIOL.
CALCIUM CARBIMIDE for therapeutic use.
CALCIUM POLYSTYRENE SULPHONATE.
CALOTROPIS GIGANTEA.
CALOTROPIS PROCERA.
CAMPHORATED OIL for therapeutic use.
CAMPHOTAMIDE.
CANAKINUMAB.
CANDESARTAN CILEXETIL.
CANDICIDIN.
CANINE TICK ANTI-SERUM.
CANTHARIDIN.
CAPECITABINE.
CAPREOMYCIN.
CAPTODIAME.
CAPTOPRIL.
CAPURIDE.
CARAMIPHEN.
CARBACHOL.
CARBAMAZEPINE.
CARBARYL for human therapeutic use.
CARBAZOCHROME.
CARBENICILLIN.
CARBENOXOLONE for internal use.
CARBETOCIN.
CARBIDOPA.
CARBIMAZOLE.
CARBOCROMEN.
CARBOPLATIN.
CARBOPROST.
CARBROMAL.
CARBUTAMIDE.
CARBUTEROL.
CARINDACILLIN.
CARISOPRODOL.
CARMUSTINE.
CARNIDAZOLE.
CARPROFEN.
CARVEDILOL.
CASPOFUNGIN.
CATHINE.
CATUMAXOMAB.
CEFACETRILE.
CEFACLOR.
CEFADROXIL.
CEFALORIDINE.
CEFAMANDOLE.
CEFAPIRIN.
CEFAZOLIN.
CEFEPIME.
CEFETAMET.
CEFIXIME.
CEFODIZIME.
CEFONICID.
CEFOPERAZONE.
CEFOTAXIME.
CEFOTETAN.
CEFOTIAM.
CEFOVECIN for veterinary use.
CEFOXITIN.
CEFPIROME.
CEFPODOXIME.
CEFQUINOME.
CEFTAROLINE FOSAMIL.
CEFSULODIN.
CEFTAZIDIME.
CEFTIBUTEN.
CEFTIOFUR.
CEFTRIAXONE.
CEFUROXIME.
CELECOXIB.
CELIPROLOL.
CEPHAELIS ACUMINATA (ipecacuanha) except in preparations containing 0.2 per cent or less of emetine.
CEPHAELIS IPECACUANHA except in preparations containing 0.2 per cent or less of emetine.
CEPHALEXIN.
CEPHALONIUM.
CEPHALOTHIN.
CEPHRADINE.
CERIVASTATIN.
CERTOLIZUMAB PEGOL.
CERULETIDE.
CETIRIZINE except when included in Schedule 2CETRORELIX.
CETUXIMAB.
CHENODEOXYCHOLIC ACID.
CHLORAL FORMAMIDE.
CHLORAL HYDRATE except in preparations for topical use containing 2 per cent or less of chloral hydrate.
CHLORALOSE except when included in Schedule 6.
CHLORAMBUCIL.
CHLORAMPHENICOL except when included in Schedule 3.
CHLORAZANIL.
CHLORCYCLIZINE.
CHLORDIAZEPOXIDE.
CHLORMERODRIN.
CHLORMETHIAZOLE.
CHLORMEZANONE.
CHLOROFORM for use in anaesthesia.
2-(4-CHLOROPHENYL)-(1,2,4)TRIAZOLO[5,1-A]ISOQUINOLINE.
CHLOROQUINE.
CHLOROTHIAZIDE.
CHLOROTRIANISENE.
CHLORPHENIRAMINE except when included in Schedule2 or 3.
CHLORPHENTERMINE.
CHLORPROMAZINE.
CHLORPROPAMIDE.
CHLORPROTHIXENE.
CHLORQUINALDOL for human topical use.
CHLORTETRACYCLINE except when included in Schedule5.
CHLORTHALIDONE.
CHLORZOXAZONE.
CHOLERA VACCINE.
CHOLESTYRAMINE (colestyramine) for human therapeutic use.
CHYMOPAPAIN for human therapeutic use.
CICLACILLIN.
CICLESONIDE.
CICLOPIROX except when included in Schedule 2 or 3.
CIDOFOVIR.
CILASTATIN.
CILAZAPRIL.
CILOSTAZOL.
CIMETIDINE except when included in Schedule 3.
CINACALCET.
CINCHOCAINE except when included in Schedule 2.
CINOXACIN.
CIPROFLOXACIN.
CISAPRIDE.
CISATRACURIUM BESYLATE.
CISPLATIN.
CITALOPRAM.
CLADRIBINE.
CLANOBUTIN.
CLARITHROMYCIN.
CLAVULANIC ACIDCLEMASTINE except when included in Schedule 3.
CLEMIZOLE.
CLENBUTEROL.
CLEVIDIPINE.
CLIDINIUM BROMIDE.
CLINDAMYCIN.
CLOBETASOL.
CLOBETASONE (clobetasone-17-butyrate) except when included in Schedule 3.
CLOCORTOLONE.
CLODRONIC ACID (includes sodium clodronate).
CLOFARABINE.
CLOFAZIMINE.
CLOFENAMIDE.
CLOFIBRATE.
CLOMIPRAMINE.
CLOMOCYCLINE.
CLONAZEPAM.
CLONIDINE.
CLOPAMIDE.
CLOPIDOGREL.
CLOPROSTENOL.
CLORAZEPATE.
CLOREXOLONE.
CLORPRENALINE.
COBALT for human therapeutic use except as dicobalt edetate in preparations for the treatment of cyanide poisoning.
CODEINE when compounded with one or more other therapeutically active substances:(a)in divided preparations containing 30 mg or less of codeine per dosage unit; or(b)in undivided preparations containing 1 per cent or less of codeine,except when included in Schedule 2 or 3.
CO-DERGOCRINE.
COLASPASE.
COLCHICINE.
COLCHICUM AUTUMNALE.
COLESTIPOL.
COLFOSCERIL PALMITATE for human therapeutic use.
COLISTIN.
CONVALLARIA KEISKI.
CONVALLARIA MAJALIS.
CORONILLA spp.
CORTICOSTERONE.
CORTICOTROPHIN.
CORTISONE.
CO-TRIMOXAZOLE.
COUMARIN for therapeutic use (excluding when present as an excipient).
CRYSTAL VIOLET for human use except when used as a dermal marker.
CUPRIMYXIN.
CURARE.
CYCLANDELATE.
CYCLIZINE except when included in Schedule 3.
CYCLOBENZAPRINE.
CYCLOHEXIMIDE.
CYCLOPENTHIAZIDE.
CYCLOPENTOLATE.
CYCLOPHOSPHAMIDE.
CYCLOPROPANE for therapeutic use.
CYCLOSERINE.
CYCLOSPORIN.
CYCLOTHIAZIDE.
CYCRIMINE.
CYMARIN.
CYPROHEPTADINE except when included in Schedule3.
CYPROTERONE.
CYSTEAMINE for human therapeutic use.
CYTARABINE.
DABIGATRAN.
DACARBAZINE.
DACLIZUMAB.
DACTINOMYCIN.
DALFOPRISTIN.
DALTEPARIN (includes dalteparin sodium).
DANAPAROID (includes danaparoid sodium).
DANTHRON for human use.
DANTROLENE.
DAPAGLIFLOZIN.
DAPOXETINE.
DAPSONE.
DAPTOMYCIN.
DARIFENACIN.
DARUNAVIR.
DERACOXIB.
DESFERRIOXAMINE.
DESFLURANE.
DESIPRAMINE.
DESIRUDIN.
DESLANOSIDE.
DESLORATADINE except when included in Schedule 2.
DESLORELIN.
DESMOPRESSIN (D.D.A.V.P. ).
DESOGESTREL.
DESONIDE.
DESOXYMETHASONE.
DESVENLAFAXINE.
DETOMIDINE.
DEXAMETHASONE.
DEXCHLORPHENIRAMINE except when included in Schedule2 or3.
DEXFENFLURAMINE.
DEXMEDETOMIDINE.
DEXTROMETHORPHAN (excluding its stereoisomers) except when included in Schedule 2.
DEXTRORPHAN (excluding its stereoisomers).
DIAMTHAZOLE.
DIAVERIDINE.
DIAZEPAM.
DIAZOXIDE.
DIBENZEPIN.
DIBOTERMIN.
DIBROMOPROPAMIDINE for therapeutic use except when included in Schedule 2.
DICHLORALPHENAZONE.
DICHLOROPHEN for human therapeutic use.
DICHLORPHENAMIDE.
DICLOXACILLIN.
DICYCLOMINE.
DIDANOSINE.
DIENESTROL.
DIENOGEST.
DIETHAZINE.
DIETHYLCARBAMAZINE for human therapeutic use.
DIETHYLPROPION.
DIFENOXIN in preparations containing, per dosage unit, 0.5mg or less of difenoxin and a quantity of atropine sulfate equivalent to at least 5per cent of the dose of difenoxin.
DIFLORASONE.
DIFLOXACIN.
DIFLUCORTOLONE.
DIFLUNISAL.
DIGITALIS LANATA.
DIGITALIS PURPUREA.
DIGITOXIN.
DIGOXIN.
DIGOXIN-SPECIFIC ANTIBODY FRAGMENT F (Ab).
DIHYDRALAZINE.
DIHYDROCODEINE when compounded with one or more other therapeutically active substances:(a)in divided preparations containing not more than 100mg of dihydrocodeine per dosage unit; or(b)in undivided preparations with a concentration of not more than 2.5per cent of dihydrocodeine,except when included in Schedule2 or 3.
DIHYDROERGOTOXINE.
DIHYDROSTREPTOMYCIN.
DIHYDROTACHYSTEROL.
DIISOPROPYLAMINE DICHLOROACETATE.
DILTIAZEM.
DIMENHYDRINATE except when included in Schedule2 or 3.
DIMERCAPROL.
DIMETHINDENE except when included in Schedule3.
DIMETHOTHIAZINE.
DIMETHOXANATE.
DIMETRIDAZOLE.
2,4-DINITROCHLOROBENZENE for therapeutic use.
DINITROCRESOLS for therapeutic use except when separately specified in these Schedules.
DINITRONAPHTHOLS for therapeutic use except when separately specified in these Schedules.
DINITROPHENOLS for therapeutic use.
DINITROTHYMOLS for therapeutic use except when separately specified in these Schedules.
DIPERODON.
DIPHEMANIL except in preparations for dermal use.
DIPHENHYDRAMINE except when included in Schedule2 or3.
DIPHENIDOL.
DIPHENOXYLATE in preparations containing, per dosage unit, 2.5mg or less of diphenoxylate and a quantity of atropine sulfate equivalent to at least 1per cent of the dose of diphenoxylate except when included in Schedule3.
DIPHENYLPYRALINE.
DIPHTHERIA TOXOID.
DIPIVEFRIN.
DIPYRIDAMOLE.
DIRITHROMYCIN.
DIRLOTAPIDE.
DISOPHENOL.
DISOPYRAMIDE.
DISTIGMINE.
DISULFIRAM for therapeutic use.
DISULPHAMIDE.
DITHIAZANINE except when included in Schedule 6.
DITIOCARB.
DOBUTAMINE.
DOCETAXEL.
DOFETILIDE.
DOLASETRON.
DOMPERIDONE.
DONEPEZIL.
DOPAMINE.
DOPEXAMINE.
DORIPENEM.
DORNASE.
DORZOLAMIDE.
DOTHIEPIN.
DOXANTRAZOLE.
DOXAPRAM.
DOXAZOSIN.
DOXEPIN.
DOXORUBICIN.
DOXYCYCLINE.
DOXYLAMINE except when included in Schedule2 or3.
DRONEDARONE.
DROPERIDOL.
DROSPIRENONE.
DUBOISIA LEICHHARDTII except when included in Schedule2.
DUBOISIA MYOPOROIDES except when included in Schedule 2.DULOXETINE.
DUTASTERIDE.
DYDROGESTERONE.
ECOTHIOPATE (includes ecothiopate iodide).
ECTYLUREA.
ECULIZUMAB.
EDROPHONIUM.
EFALIZUMAB.
EFAVIRENZ.
EFLORNITHINE.
ELETRIPTAN.
ELTENAC.
ELTROMBOPAG.
EMEPRONIUM.
EMETINE except in preparations containing 0.2per cent or less of emetine.
EMTRICITABINE.
ENALAPRIL.
ENFLURANE for therapeutic use.
ENFUVIRTIDE.
ENOXACIN.
ENOXAPARIN.
ENOXIMONE.
ENROFLOXACIN.
ENTACAPONE.
ENTECAVIR.
EPHEDRA spp. except in preparations containing 0.001 per cent or less of ephedrine.
EPICILLIN.
EPINASTINE.
EPIRUBICIN.
EPROSARTAN.
EPTIFIBATIDE.
ERGOMETRINE.
ERGOT.
ERGOTAMINE.
ERGOTOXINE.
ERIBULIN MESYLATE.
ERLOTINIB.
ERTAPENEM.
ERYSIMUM spp.
ERYTHROMYCIN.
ESCITALOPRAM.
ESMOLOL.
ESOMEPRAZOLE.
ESTRAMUSTINE.
ESTROPIPATE (piperazine oestrone sulfate).
ETANERCEPT.
ETHACRYNIC ACID.
ETHAMBUTOL.
ETHAMIVAN.
ETHANOLAMINE in preparations for injection.
ETHCHLORVYNOL.
ETHER for use in anaesthesia.
ETHINAMATE.
ETHINYLOESTRADIOL.
ETHIONAMIDE.
ETHISTERONE.
ETHOGLUCID.
ETHOHEPTAZINE.
ETHOPROPAZINE.
ETHOSUXIMIDE.
ETHOTOIN.
ETHOXZOLAMIDE.
ETHYL CHLORIDE for human therapeutic use.
ETILEFRIN.
ETIPROSTON.
ETODOLAC.
ETOFENAMATE except when included in Schedule 2.
ETONOGESTREL.
ETOPOSIDE.
ETORICOXIB.
ETRAVIRINE.
EVEROLIMUS.
EXEMESTANE.
EXENATIDE.
EZETIMIBE.
FAMCICLOVIR except when included in Schedule 3.
FAMOTIDINE except when included in Schedule 2.
FELBINAC except when included in Schedule 2.
FELODIPINE.
FELYPRESSIN.
FENBUFEN.
FENCAMFAMIN.
FENCLOFENAC.
FENFLURAMINE.
FENOFIBRATE.
FENOLDOPAM.
FENOPROFEN.
FENOTEROL.
FENPIPRAMIDE.
FENPIPRANE.
FENPROPOREX.
FENPROSTALENE.
FINASTERIDE.
FINGOLIMOD.
FIROCOXIB.
FLECAINIDE.
FLEROXACIN.
FLOCTAFENINE.
FLORFENICOL.
FLUANISONE.
FLUCLOROLONE.
FLUCLOXACILLIN.
FLUCONAZOLE except when included in Schedule 3.
FLUCYTOSINE.
FLUDARABINE.
FLUDROCORTISONE.
FLUFENAMIC ACID.
FLUMAZENIL.
FLUMETHASONE.
FLUMETHIAZIDE.
FLUNISOLIDE.
FLUNIXIN MEGLUMINE.
FLUOCINOLONE.
FLUOCINONIDE.
FLUOCORTIN.
FLUOCORTOLONE.
FLUORESCEIN in preparations for injection.
FLUORIDES in preparations for human use except when included in or expressly excluded from Schedule 2 or 3.
FLUOROMETHOLONE.
FLUOROURACIL.
FLUOXETINE.
FLUPENTHIXOL.
FLUPHENAZINE.
FLUPROSTENOL.
FLURANDRENOLONE.
FLURAZEPAM.
FLURBIPROFEN except when included in Schedule 2.
FLUROXENE for human therapeutic use.
FLUSPIRILENE.
FLUTAMIDE.
FLUTICASONE except when included in Schedule 2.
FLUVASTATIN.
FLUVOXAMINE.
FOLIC ACID in preparations for human use for injection.
FOLINIC ACID in preparations for human use for injection.
FOLLICLE-STIMULATING HORMONE except when separately specified in this Schedule.
FOMIVIRSEN.
FURAZOLIDONE.FUROSEMIDE (frusemide).
FUSIDIC ACID.
GABAPENTIN.
GALANTAMINE.
GALANTHUS spp.
GALLAMINE.
GALSULFASE.
GANCICLOVIR.
GANIRELIX.
GATIFLOXACIN.
GEFITINIB.
GEMCITABINE.
GEMEPROST.
GEMFIBROZIL.
GEMIFLOXACIN.
GEMTUZUMAB OZOGAMICIN.
GENTAMICIN.
GESTODENE.
GESTONORONE.
GESTRINONE.
GHRH INJECTABLE PLASMID.
GITALIN.
GLATIRAMER ACETATE.
GLIBENCLAMIDE.
GLIBORNURIDE.
GLICLAZIDE.
GLIMEPIRIDE.
GLIPIZIDE.
GLISOXEPIDE.
GLUTATHIONE for parenteral use.
GLYCERYL TRINITRATE except when included in Schedule 3.
GLYCOPYRRONIUM in preparations for injection.
GLYMIDINE.
GnRH VACCINE.
GOLIMUMAB.
GONADORELIN.
GONADOTROPHIC HORMONES except when separately specified in this Schedule.
GOSERELIN.
GRAMICIDIN.
GRANISETRON.
GREPAFLOXACIN.
GRISEOFULVIN.
GUANABENZ.GUANACLINE.
GUANETHIDINE.
GUANIDINE for therapeutic use.
HACHIMYCIN.
HAEMATIN.
HAEMOPHILUS INFLUENZAE VACCINE.
HALCINONIDE.
HALOFANTRINE.
HALOFENATE.
HALOFUGINONE in preparations containing 0.1 per cent or less of halofuginone for the treatment of animals.
HALOPERIDOL.
HALOTHANE for therapeutic use.
HEMEROCALLIS (Hemerocallis flava).
HEPARINS for internal use except when separately specified in this Schedule.
HEPATITIS A VACCINE.
HEPATITIS B VACCINE.
HETACILLIN.
HEXOPRENALINE.
HISTAMINE for therapeutic use except in preparations containing 0.5 per cent or less of histamine.
HMG-CoA REDUCTASE INHIBITORS (including "statins") except when separately specified in these Schedules.
HOMATROPINE.
HUMAN CHORIONIC GONADATROPHIN except in pregnancy test kits.
HUMAN PAPILLOMAVIRUS VACCINE.
HYPOTHALAMIC RELEASING FACTORS except when separately specified in this Schedule.
HYPROMELLOSE in preparations for injection.
IBAFLOXACIN for veterinary use.
IBANDRONIC ACID.
IBOGAINE.
IBRITUMOMAB.
IBUFENAC.
IBUPROFEN except:(a)when included in or expressly excluded from Schedule 2 or 3; or(b)in preparations for dermal use.
IBUTEROL.
IBUTILIDE.
ICATIBANT.
IDARUBICIN.
IDOXURIDINE except in preparations containing 0.5 per cent or less of idoxuridine for dermal use.
IDURSULFASE.
IFOSFAMIDE.
ILOPROST.
IMATINIB.
IMIDAPRIL.
IMIGLUCERASE.
IMIPENIM.
IMIPRAMINE.
IMIQUIMOD.
IMMUNOGLOBULINS for human parenteral use except when separately specified in these Schedules.
INDACATEROL.
INDAPAMIDE.
INDINAVIR.
INDOMETHACIN except when included in Schedule 2.
INDOPROFEN.
INDORAMIN.
INFLIXIMAB.
INSULINS.
INTERFERONS.
INTERLEUKINS except when separately specified in these Schedules.
IODOTHIOURACIL.
IPILIMUMAB.
IPRATROPIUM except when included in Schedule 2.
IPRIFLAVONE.
IPRINDOLE.
IPRONIAZID.
IRBESARTAN.
IRINOTECAN.
IRON COMPOUNDS in injectable preparations for human use.
ISOAMINILE.
ISOAMYL NITRITE.
ISOBUTYL NITRITE.
ISOCARBOXAZID.
ISOCONAZOLE except when included in Schedule 2, 3 or 6.
ISOETARINE.
ISOFLURANE for therapeutic use.
ISOMETHEPTENE.
ISONIAZID.
ISOPRENALINE.
ISOPRINOSINE.
ISOPROPAMIDE except when included in Schedule2.
ISOSORBIDE DINITRATE except when included in Schedule 3.
ISOSORBIDE MONONITRATE.
ISOXICAM.ISOXSUPRINE.
ISRADIPINE.
ITRACONAZOLE.
IVABRADINE.
IXABEPILONE.JAPANESE ENCEPHALITIS VACCINE.
KANAMYCIN.
KETANSERIN except in topical veterinary preparations containing 0.5 per cent
or less of ketanserin.
KETAZOLAM.
KETOTIFEN except when included in Schedule 2.
KHELLIN.
LABETALOL.
LACIDIPINE.
LACOSAMIDE.
LAMIVUDINE.
LAMOTRIGINE.
LANATOSIDES.
LANREOTIDE.
LANSOPRAZOLE except when included in Schedule 3.
LANTHANUM for therapeutic use.
LAPATINIB.
LARONIDASE.
LAROPIPRANT.
LATAMOXEF.
LATANOPROST.
LAUDEXIUM.
LENOGRASTIM.
LEPIRUDIN.
LEPTAZOL.
LERCANIDIPINE.
LETROZOLE.
LEUPRORELIN.
LEVALLORPHAN.
LEVOCABASTINE except when included in Schedule2.
LEVODOPA.
LEVOMEPROMAZINE.
LEVONORGESTREL except when included in Schedule 3.
LEVOSIMENDAN.
LIDOFLAZINE.
LISURIDE.
LITHIUM for therapeutic use except:(a)when included in Schedule 2; (b) when present as an excipient in preparations for dermal use containing 0.25 per cent or less of lithium; or(c)in preparations containing 0.01 per cent or less of lithium.
LIXISENATIDE.
LODOXAMIDE except when included in Schedule2.
LOFEXIDINE.
LOGIPARIN for internal use.
LOMEFLOXACIN.
LOMUSTINE.
LOPRAZOLAM.
LORACARBEF.
LORATADINE except when included in Schedule 2.
LORAZEPAM.
LORMETAZEPAM.
LOSARTAN.
LOXAPINE.
LUMEFANTRINE.
LUMIRACOXIB.
LYMECYCLINE.
MAFENIDE except when included in Schedule 6.
MANDRAGORA OFFICINARUM.
MANNOMUSTINE.
MAPROTILINE.
MARAVIROC.
MARBOFLOXACIN.
MAROPITANT.
MAVACOXIB.
MAZINDOL.
MEASLES VACCINE.
MEBANAZINE.
MEBEVERINE.
MEBHYDROLIN.
MEBUTAMATE.
MECAMYLAMINE.
MECASERMIN.
MECILLINAM.
MECLOCYCLINE.
MECLOFENAMATE.
MECLOFENOXATE.
MECLOZINE except when included in Schedule 2.
MEDAZEPAM.
MEDETOMIDINE.
MEDIGOXIN (methyldigoxin).
MEDROXYPROGESTERONE.
MEDRYSONE.
MEFENAMIC ACID except when included in Schedule2.
MEFENOREX.
MEFLOQUINE.
MEFRUSIDE.
MEGESTROL.
MELAGATRAN.
MELATONIN for human use.
MELENGESTROL except when included in Schedule 6.
MELOXICAM.
MELPHALAN.
MEMANTINE.
MENINGOCOCCAL VACCINE.
MENOTROPHIN.
MEPACRINE.
MEPENZOLATE.
MEPHENESIN.
MEPHENTERMINE.
MEPINDOLOL.
MEPIVACAINE.
MEPROBAMATE.
MEPTAZINOL.
MEPYRAMINE except when included in Schedule 2 or 3.
MEQUITAZINE.
MERCAPTOMERIN.
MERCAPTOPURINE.
MERCUROCHROME except when included in Schedule 2 or 6.
METHICILLIN.
METHIMAZOLE.
METHISAZONE.
METHIXENE.
METHOCARBAMOL.
METHOHEXITONE.
METHOIN.
METHOTREXATE.
METRIFONATE (trichlorfon) for human therapeutic use.
METRONIDAZOLE.
METYRAPONE.
MEXILETINE.
MEZLOCILLIN.
MIANSERIN.
MIBEFRADIL.
MIDAZOLAM.
MIDODRINE.
MIFEPRISTONE.
MIGLITOL.
MIGLUSTAT.
MILBEMYCIN OXIME except when included in Schedule 5.
MILRINONE.
MINOCYCLINE.
MINOXIDIL except when included in Schedule 2.
MIRTAZAPINE.
MISOPROSTOL.
MITOBRONITOL.
MITOMYCIN.
MITOTANE.
MITOXANTRONE.
MITRATAPIDE.
MIVACURIUM CHLORIDE.
MOCLOBEMIDE.
MODAFINIL.
MOLGRAMOSTIM.
MOLINDONE.
MOMETASONE except when included in Schedule 2.
MOPERONE.
MORAZONE.
MORICIZINE.
MOTRAZEPAM.
MOTRETINIDE.
MOXIDECTIN in preparations for injection containing 10 per cent or less of moxidectin except when included in Schedule 5.
MOXIFLOXACIN.
MOXONIDINE.
MUMPS VACCINE.
MUPIROCIN.
MURAGLITAZAR.
MUROMONAB.
MUSTINE (nitrogen mustard).
MYCOPHENOLIC ACID (includes mycophenolate mofetil).
NABUMETONE.
NADOLOL.
NADROPARIN.
NAFARELIN.
NAFTIDROFURYL.
NALBUPHINE.
NALIDIXIC ACID.
NALORPHINE.
NALOXONE.
NALTREXONE.
NEDOCROMIL.
NEFAZODONE.
NEFOPAM.
NELFINAVIR (includes nelfinavir mesylate).
NEOMYCIN.
NEOSTIGMINE.
NEPAFENAC.
NERIUM OLEANDER.
NESIRITIDE.
NETILMICIN.
NEVIRAPINE.
NIALAMIDE.
NICARDIPINE.
NICERGOLINE.
NICOFURANOSE.
NICORANDIL.
NICOTINE in preparations for human therapeutic use except for use as an aid in withdrawal from tobacco smoking in preparations for oromucosal or transdermal use.
NIRIDAZOLE.
NISOLDIPINE.
NITISINONE.
NITRAZEPAM.
NITRENDIPINE.
NITRIC OXIDE for human therapeutic use.
NITROFURANTOIN.
NITROFURAZONE.
NITROUS OXIDE for therapeutic use.
NITROXOLINE.
NIZATIDINE except when included in Schedule 2.
NOMEGESTROL.
NOMIFENSINE.
NORADRENALINE.
NOVOBIOCIN.
NOXIPTYLINE.
NYSTATIN except when included in Schedule 2 or 3.
OCTAMYLAMINE.
OCTATROPINE.
OCTREOTIDE.
OCTYL NITRITE.
OESTRADIOL except when included in Schedule 5.
OESTRIOL.
OESTROGENS except when separately specified in these Schedules.
OESTRONE.
OFATUMUMAB.
OFLOXACIN.
OLANZAPINE.
ORPHENADRINE.ORTHOPTERIN.
OSELTAMIVIR.
OUABAIN.
OXAPROZIN.
OXAZEPAM.
OXCARBAZEPINE.
OXEDRINE for human internal use except in preparations labelled with a recommended daily dose of 30 mg or less of oxedrine.
OXETACAINE (oxethazaine) except when included in Schedule 2.
OXITROPIUM.
OXOLAMINE.
OXOLINIC ACID.
OXPENTIFYLLINE (pentoxifylline).
OXPRENOLOL.
OXYBUPROCAINE.
OXYBUTYNIN.
OXYPHENBUTAZONE.
OXYPHENCYCLIMINE.
OXYPHENONIUM.
OXYTETRACYCLINE except when included in Schedule5.
OXYTOCIN.
PACLITAXEL.
PALIFERMIN.
PALIPERIDONE.
PALIVIZUMAB.
PALONOSETRON.
PAMAQUIN.
PAMIDRONIC ACID (includes disodium pamidronate).
PARACETAMOL:(a)when combined with aspirin or salicylamide or any derivative of these substances except when separately specified in these Schedules;(b)when combined with ibuprofen in a primary pack containing more than 30 dosage units;(c)in slow release tablets or capsules containing more than 665 mg of paracetamol;(d)in non-slow release tablets or capsules containing more than 500 mg of paracetamol;
(e)in individually wrapped powders or sachets of granules each containing more than 1000 mg of paracetamol;(f)for injection.
PARALDEHYDE.
PARAMETHADIONE.
PARAMETHASONE.
PARECOXIB.
PARICALCITOL.
PAROMOMYCIN.
PAROXETINE.
PAZOPANIB.
PECAZINE.
PEFLOXACIN.
PEGAPTANIB.
PEGFILGRASTIM.
PEGINTERFERON.
PEGVISOMANT.
PEMETREXED.
PEMOLINE.
PEMPIDINE.
PENBUTOLOL.
PENCICLOVIR except when included in Schedule2.
PENETHAMATE.
PENICILLAMINE.
PENTAERYTHRITYL TETRANITRATE.
PENTAGASTRIN.
PENTAMETHONIUM.
PENTAMIDINE (includes pentamidine isethionate).
PENTHIENATE.
PENTOBARBITONE when packed and labelled for injection.
PENTOLINIUM.
PENTOSAN POLYSULFATE SODIUM.
PERGOLIDE.
PERHEXILINE.
PERICYAZINE.
PERINDOPRIL.
PERMETHRIN for human therapeutic use except in preparations containing 5 per cent or less of permethrin.
PERPHENAZINE.
PERTUSSIS ANTIGEN.
PHENACEMIDE.
PHENACETIN for therapeutic use (excluding when present as an excipient).
PHENAGLYCODOL.
PHENAZONE except when included in Schedule2 or 5.
PHENAZOPYRIDINE.
PHENELZINE.
PHENETICILLIN.
PHENFORMIN.
PHENGLUTARIMIDE.
PHENINDIONE.
PHENIRAMINE except when included in Schedule2 or 3.
PHENISATIN.
PHENOBARBITONE.
PHENOL in preparations for injection.
PHENOLPHTHALEIN for human therapeutic use
PHENOXYBENZAMINE.
PHENOXYMETHYLPENICILLIN.
PHENSUXIMIDE.
PHENTHIMENTONIUM.
PHENTOLAMINE.
PHENYLBUTAZONE.
PILOCARPINE except in preparations containing 0.025per cent or less of pilocarpine.
PIMECROLIMUS.
PIMOBENDAN.
PIMOZIDE.
PINACIDIL.
PINDOLOL.
PIOGLITAZONE.
PIPECURONIUM.
PIPEMIDIC ACID.
PIPENZOLATE.
PIPOTHIAZINE.
PIPRADROL.
PIRACETAM.
PIRBUTEROL.
PIRENOXINE (catalin).
PIRENZEPINE.
PIRETANIDE.
PIROXICAM except in preparations for dermal use.
PIRPROFEN.
PITAVASTATIN.
PITUITARY HORMONES except when separately specified in these Schedules.
PIVAMPICILLIN.
PIZOTIFEN.
PLICAMYCIN.
PLERIXAFOR.
PNEUMOCOCCAL VACCINE.
POLYMYXIN.
POLYSULFATED GLYCOSAMINOGLYCANS in preparations for injection, except when separately specified in these Schedules.
POLYTHIAZIDE.
PORACTANT.
POSACONAZOLE.
POTASSIUM BROMIDE for therapeutic use.
PRASUGREL.
PRAVASTATIN.
PRAZEPAM.
PRAZIQUANTEL for human therapeutic use.
PRAZOSIN.
PREDNISOLONE.
PREDNISONE.
PREGABALIN.
PREGNENOLONE.
PRENALTEROL.
PRENYLAMINE.
PRILOCAINE except when included in Schedule 2.
PRIMAQUINE.
PRIMIDONE.
PROBENECID.
PROBUCOL.
PROCAINAMIDE.
PROCAINE.
PROCAINE PENICILLIN.
PROCARBAZINE.
PROCHLORPERAZINE except when included in Schedule3.
PROCYCLIDINE except when included in Schedule2.
PROGESTERONE except when included in Schedule 5.
PROGESTOGENS except when separately specified in these Schedules.
PROGLUMIDE.
PROGUANIL.
PROLINTANE.
PROMAZINE.
PROMETHAZINE except when included in Schedule2 or 3.
PROMOXOLANE.
PROPAFENONE.
PROPAMIDINE for therapeutic use except when included in Schedule 2.
PROPANIDID.
PROPANTHELINE.
PROPENTOFYLLINE.
PROPRANOLOL.
PROPYLHEXEDRINE.
PROPYLTHIOURACIL.
PROPYPHENAZONE.
PROQUAZONE.
PROSCILLARIDIN.
PROSTAGLANDINS except when separately specified in this Schedule.
PROSTIANOL.
PROTAMINE.
PROTHIONAMIDE.
PROTHIPENDYL.
PROTIRELIN.
PROTOVERATRINES.
PROTRIPTYLINE.
PROXYMETACAINE.
PSEUDOEPHEDRINE except when included in Schedule 3.
PYRAZINAMIDE.
PYRIDINOLCARBAMATE.
PYRIDOSTIGMINE.
RAPACURONIUM.
RASAGILINE.
RASBURICASE.
RAUWOLFIA SERPENTINA.
RAUWOLFIA VOMITORIA.
RAZOXANE.
REBOXETINE.
RED YEAST RICE for human therapeutic use.
REMOXIPRIDE.
REPAGLINIDE.
RESERPINE.
RETEPLASE.
RIBAVIRIN.
RIFABUTIN.
RIFAMPICIN.
RIFAMYCIN.
RIFAPENTINE.
RIFAXIMIN.
RILPIVIRINE.
RILUZOLE.
RIMEXOLONE.
RIMITEROL.
RIMONABANT.
RISEDRONIC ACID.
RISPERIDONE.
RITODRINE.
RITONAVIR.
RITUXIMAB.
RIVAROXABAN.
RIVASTIGMINE.
RIZATRIPTAN.
ROBENACOXIB.
ROCURONIUM.
ROFECOXIB.
ROFLUMILAST.
ROLITETRACYCLINE.
ROMIFIDINE.
ROMIPLOSTIM.
RONIDAZOLE.
ROPINIROLE.
ROPIVACAINE.
ROSIGLITAZONE.
ROSOXACIN.
ROSUVASTATIN.
ROTIGOTINE.
RUBELLA VACCINE.
RUBOXISTAURIN.
RUPATADINE.
SALBUTAMOL except when included in Schedule3.
SALCATONIN.
SALICYLAMIDE when combined with aspirin, caffeine or paracetamol or any derivative of these substances.
SERMORELIN.
SERTINDOLE.
SERTRALINE.
SEVELAMER.
SEVOFLURANE.
SEX HORMONES and all substances having sex hormonal activity except when separately specified in these Schedules.
SIBUTRAMINE.
SILDENAFIL.
SILICONES for intra-ocular use.
SILVER SULFADIAZINE.
SIMVASTATIN.
SIROLIMUS.
SISOMICIN (sisomycin).
SITAGLIPTIN.
SODIUM BROMIDE for therapeutic use.
SODIUM CELLULOSE PHOSPHATE for human internal use.
SODIUM CROMOGLYCATE except when included in Schedule2.
SODIUM MORRHUATE in preparations for injection.
SODIUM NITROPRUSSIDE for human therapeutic use.
SODIUM PHOSPHATE in preparations for oral laxative use.
SODIUM POLYSTYRENE SULPHONATE for human therapeutic use.
SODIUM SALICYLATE in preparations for injection for the treatment of animals.
SODIUM TETRADECYLSULFATE in preparations for injection.
SOLASODINE.
SOLIFENACIN.
SOMATOSTATIN.
SOMATOTROPIN EQUINE.
SONTOQUINE.
SORAFENIB.
SOTALOL.
SPARFLOXACIN.
SPARTEINE.
SPECTINOMYCIN.
SPIRAMYCIN.
SPIRAPRIL.
SPIRONOLACTONE.
STROPHANTHINS.
STROPHANTHUS spp.
STRYCHNINE in preparations containing 1.5per cent or less of strychnine for the treatment of animals.
STRYCHNOS spp. except in preparations containing 1 mg or less per litre or per kilogram of strychnine.
STYRAMATE.
SUCCIMER.
SUGAMMADEX.
SULBACTAM.
SULCONAZOLE except when included in Schedule 2.
SULFACETAMIDE except when included in Schedule 3 or 5.
SULFADIAZINE except when included in Schedule 5.
SULFADIMETHOXINE.
SULFADIMIDINE except when included in Schedule 5.
SULFADOXINE.
SULFAFURAZOLE.
SULFAGUANIDINE.
SULFAMERAZINE except when included in Schedule 5.
SULFAMETHIZOLE.
SULFAMETHOXAZOLE.
SULFAMETHOXYDIAZINE.
SULFAMETHOXYPYRIDAZINE.
SULFAMETROLE.
SULFAMONOMETHOXINE.
SULFAMOXOLE.
SULFAPHENAZOLE.
SULFAPYRIDINE.
SULFAQUINOXALINE.
SULFASALAZINE.
SULFATHIAZOLE except when included in Schedule 5.
SULFATROXAZOLE.
SULFINPYRAZONE.
SULFOMYXIN.
SUNITINIB.
SUPROFEN.
SUTILAINS.
SUXAMETHONIUM.
SUXETHONIUM.
TACRINE.
TACROLIMUS.
TADALAFIL.
TAFLUPROST.
TALIGLUCERASE ALFA.
TAMOXIFEN.
TAMSULOSIN.
TANACETUM VULGARE except in preparations containing 0.8 per cent or less of oil of tansy.
TASONERMIN.
TAZAROTENE.
TAZOBACTAM.
T-CELL RECEPTOR ANTIBODY.
TEGAFUR.
TEGASEROD.
TELITHROMYCIN.
TEICOPLANIN.
TELBIVUDINE.
TELMISARTAN.
TEMAZEPAM.
TEMOZOLOMIDE.
TEMSIROLIMUS.
TENECTEPLASE.
TENIPOSIDE.
TENOFOVIR.
TENOXICAM.
TEPOXALIN.
TERAZOSIN.
TETANUS ANTITOXIN except when used for short-term protection or treatment of tetanus in animals.
TETANUS TOXOID for human use.
TETRABENAZINE.
TETRACOSACTRIN.
TETRACYCLINE except when included in Schedule5.
TETRAETHYLAMMONIUM.
TETROXOPRIM.
THENYLDIAMINE.
THEOPHYLLINE except when included in Schedule3.
THEVETIA PERUVIANA.
THEVETIN.
THIACETARSAMIDE in preparations for the prevention or treatment of heartworm in dogs.
THIAMBUTOSINE.
THIAZOSULFONE.
THIETHYLPERAZINE.
THIOACETAZONE.
THIOCARLIDE.
THIOGUANINE.
THIOPENTONE.
THIOPROPAZATE.
THIOPROPERAZINE.
THIORIDAZINE.
THIOSTREPTON.
THIOTEPA.
THIOTHIXENE.
THIOURACIL.
THIOUREA for therapeutic use except in preparations containing 0.1 per cent or less of thiourea.
THYMOXAMINE (includes thymoxamine hydrochloride).
THYROID except when separately specified in this Schedule.
THYROTROPHIN.
THYROXINE (includes thyroxine sodium).
TIAGABINE.
TIAMULIN.
TIAPROFENIC ACID.
TIARAMIDE.
TIBOLONE.
TICAGRELOR.
TICARCILLIN.
TICLOPIDINE.
TIEMONIUM.
TIENILIC ACID.
TIGECYCLINE.
TIGLOIDINE.
TILETAMINE.
TILMICOSIN.
TILUDRONIC ACID (includes disodium tiludronate).
TIMOLOL.
TINIDAZOLE.
TINZAPARIN (includes tinzaparin sodium).
TOXOIDS for human parenteral use except when separately specified in these Schedules.
TRAMADOL.
TRANDOLAPRIL.
TRANEXAMIC ACID.
TRANYLCYPROMINE.
TRASTUZUMAB.
TRAVOPROST.
TRAZODONE.
TREPROSTINIL.
TRETAMINE.
TRIACETYLOLEANDOMYCIN.
TRIAMCINOLONE except when included in Schedule 2 or 3.
TRIAMTERENE.
TRIAZIQUONE.
TRIAZOLAM.
TRICHLORMETHIAZIDE.
TRICHLOROACETIC ACID for human dermal use except when in preparations containing 12.5per cent or less of trichloroacetic acid for the treatment of warts other than anogenital warts.
TRICHLOROETHYLENE for therapeutic use.
TRICLOFOS.
TRICYCLAMOL.
TRIDIHEXETHYL.
TRIFLUOPERAZINE.
TRIFLUPERIDOL.
TRIFLUPROMAZINE.
TRILOSTANE.
TRIMEPRAZINE except when included in Schedule2 or 3.
TRIMETAPHAN.
TRIMETHOPRIM.
TRIMIPRAMINE.
TRIMUSTINE.
TRINITROPHENOL (excluding its derivatives) in preparations for human therapeutic use.
TRIOXYSALEN.
TRIPELENNAMINE.
TRIPLE ANTIGEN VACCINE.
TRIPROLIDINE except when included in Schedule2 or 3.
TRIPTORELIN.
TROGLITAZONE.
TROMETAMOL in preparations for injection except in preparations containing 3 per cent or less of trometamol.
TROPICAMIDE.
TROPISETRON.
TROVAFLOXACIN.
TROXIDONE.
TRYPTOPHAN for human therapeutic use except in preparations labelled with a recommended daily dose of 100 mg or less of tryptophan.
TUBERCULIN.
TUBOCURARINE.
TULATHROMYCIN.
TULOBUTEROL.
TYPHOID VACCINE.
UNOPROSTONE.
URACIL.
URAPIDIL.
URETHANE (excluding its derivatives) for therapeutic use.
UROKINASE.
URSODEOXYCHOLIC ACID.
USTEKINUMAB.
VACCINES for human therapeutic use except when separately specified in this Schedule.
VACCINIA VIRUS VACCINE.
VALACICLOVIR.
VALDECOXIB.
VALGANCICLOVIR.
VALNOCTAMIDE.
VALPROIC ACID.
VALSARTAN.
VANCOMYCIN.
VARDENAFIL.
VARENICLINE.
VARICELLA VACCINE.
VASOPRESSIN.
VECURONIUM.
VEDAPROFEN.
VELAGLUCERASE ALFA.
VEMURAFENIB.
VENLAFAXINE.
VERAPAMIL.
VERATRUM spp. except when separately specified in this Schedule.
VERNAKALANT.
VERTEPORFIN.
VIDARABINE.
VIGABATRIN.
VILDAGLIPTIN.
VILOXAZINE.
VINBLASTINE.
VINCAMINE.
VINCRISTINE.
VINDESINE.
VINFLUNINE.
VINORELBINE.
VINYL ETHER for therapeutic use.
VIRGINIAMYCIN except when included in Schedule 5.
VISNADINE.
VITAMIN D for human internal therapeutic use except in preparations containing 25 micrograms or less of Vitamin D per recommended daily dose.VORICONAZOLE.
VORINOSTAT.
WARFARIN for therapeutic use.
XAMOTEROL.
XANTHINOL NICOTINATE.
XIMELAGATRAN.
XIPAMIDE.
XYLAZINE.
YOHIMBINE.
ZAFIRLUKAST.
ZALCITABINE.
ZALEPLON.
ZANAMIVIR .
ZERANOL except when included in Schedule6.
ZIDOVUDINE.
ZILPATEROL.
ZIMELDINE.
ZIPRASIDONE.ZOLAZEPAM.
ZOLEDRONIC ACID.
ZOLMITRIPTAN.
ZOLPIDEM.
ZONISAMIDE.
ZOPICLONE.
ZOXAZOLAMINE.
ZUCLOPENTHIXOL.

[top]Schedules 5-7


I have left this list blank as it is primarily related to poisons of moderate to extreme danger and are not drugs of consumption. This schedule is for household chemicals, insecticides and industrial chemicals.

[top]Schedule 8


ACETYLDIHYDROCODEINE.
ACETYLMETHADOL.
ACETYLMORPHINES.

ALFENTANIL.
ALPHACETYLMETHADOL.
ALPHAPRODINE.
AMPHETAMINE.
AMYLOBARBITONE
except when included in Schedule 4. ANILERIDINE.
BENZYLMORPHINE. BEZITRAMIDE. BUPRENORPHINE. BUTOBARBITONE. BUTORPHANOL. CARFENTANYL. COCAINE.
CODEINE except when included in Schedule 2, 3 or 4.
CODEINE-N-OXIDE.
CONCENTRATE OF POPPY STRAW (the material arising when poppy straw has entered into a process for concentration of its alkaloids).
4-CYANO-1-METHYL-4-PHENYLPIPERIDINE (Pethidine intermediate A). CYCLOBARBITONE.
DEXAMPHETAMINE.
DEXTROMORAMIDE.

DEXTROPROPOXYPHENE except when included in Schedule 4.
DIFENOXIN
except when included in Schedule 4. DIHYDROCODEINE except when included in
DIPHENOXYLATE except when included in Schedule 3 or 4.
DIPIPANONE.
# DRONABINOL (
delta-9-tetrahydrocannabinol) when prepared and packed for therapeutic use. DROTEBANOL.
ETHYLAMPHETAMINE.
ETHYLMORPHINE
except when included in Schedule 2 or 4.
FENTANYL.
FLUNITRAZEPAM.
HYDROCODONE.
HYDROMORPHINOL.
HYDROMORPHONE.
KETAMINE.
LEVAMPHETAMINE.
LEVOMETHAMPHETAMINE.
LEVOMORAMIDE.
LEVORPHANOL (excluding its stereoisomers).
METHADONE.
METHYLAMPHETAMINE.
METHYLDIHYDROMORPHINE.
METHYLPHENIDATE.
1-METHYL-4-PHENYLPIPERIDINE-4-CARBOXYLIC ACID (Pethidine intermediate C). MORPHINE.
MORPHINE METHOBROMIDE.
MORPHINE-N-OXIDE.
NABILONE.

NABIXIMOLS (botanical extract of Cannabis sativa which includes the following cannabinoids: tetrahydrocannabinol, cannabidiol, cannabinol, cannabigerol, cannabichromene, cannabidiolic acid, tetrahydrocannabinolic acid, tetrahydrocannabivarol, and cannabidivarol, where tetrahydrocannabinol and cannabidiol (in approximately equal proportions) comprise not less than 90 per cent of the total cannabinoid content) in a buccal spray for human therapeutic use.
OPIUM except the alkaloids noscapine in Schedule 2 and papaverine when included in Schedule 2 or 4. OXYCODONE.
OXYMORPHONE.
PENTAZOCINE.

PENTOBARBITONE except when included in Schedule 4. PETHIDINE.
PHENDIMETRAZINE.
PHENMETRAZINE.

PHENOPERIDINE.
4-PHENYLPIPERIDINE-4-CARBOXYLIC ACID ETHYL ESTER (Pethidine intermediate B). PHOLCODINE
except when included in Schedule 2 or 4.
PIRITRAMIDE.
PROPIRAM.
QUINALBARBITONE.
RACEMORAMIDE.
REMIFENTANIL.
SECBUTOBARBITONE.
SUFENTANIL.
TAPENTADOL.
THEBACON.
THEBAINE.
TILIDINE.

[top]Schedule 9



ACETORPHINE.
ACETYL-ALPHA-METHYLFENTANYL.
ALKOXYAMPHETAMINES and substituted alkoxyamphetamines except when separately specified in these Schedules.
ALKOXYPHENYLETHYLAMINES and substituted alkoxyphenylethylamines except when separately specified in these Schedules.
ALKYLTHIOAMPHETAMINES and substituted alkylthioamphetamines except when separately specified in these Schedules.
ALLYLPRODINE.
ALPHAMEPRODINE.
ALPHA-METHYLFENTANYL.
ALPHA-METHYLTHIOFENTANYL.
ALPHAMETHADOL.
2-AMINO-1-(2,5-DIMETHOXY-4-METHYL)PHENYLPROPANE
5-(2-AMINOPROPYL)INDAN and substituted 5-(2-aminopropyl)indans except when separately specified in these
BENZETHIDINE.
BENZOYLINDOLES except when separately specified in these Schedules. BENZYLPIPERAZINE *(BZP).
BETACETYLMETHADOL.
BETA-HYDROXYFENTANYL. BETA-HYDROXY-3-METHYLFENTANYL.

BETAMEPRODINE.
BETAMETHADOL.
BETAPRODINE. 1-(8-BROMOBENZO[1,2-B;4,5-B]DIFURAN-4-YL)-2-AMINOPROPANE

CANNABIS except: (a) when separately specified in these Schedules; or (b) processed hemp fibre containing 0.1 per cent or less of tetrahydrocannabinol and products manufactured from such fibre.
CATHINONE.
CLONITAZENE.
COCA LEAF.
CODOXIME.
4-CYANO-2-DIMETHYLAMINO-
4,4‘-DIPHENYLBUTANE. CYCLOHEXYLPHENOLS except when separately specified in these Schedules.
DESOMORPHINE.

DIAMPROMIDE.
DIBENZOPYRANS except when separately specified in these Schedules.
DIETHYLTHIAMBUTENE
DIMENOXADOL.
DIMEPHEPTANOL.
2,5-DIMETHOXYAMPHETAMINE *(DMA).
2,5-DIMETHOXY-4-BROMOAMPHETAMINE *(DOB).
2,5-DIMETHOXY-4-ETHYL-a-AMPHETAMINE *(DOET).
2,5-DIMETHOXY-4-ETHYLTHIOPHENETHYLAMINE *(2C-T-2).
2,5-DIMETHOXY-4-IODOPHENETHYLAMINE *(2C-I).
2,5-DIMETHOXY-4-(N)-PROPYLTHIOPHENETHYLAMINE *(2C-T-7).
3-(2-DIMETHYLAMINOETHYL)-4-HYDROXYINDOLE *(PSILOCINE or PSILOTSIN).
3-(1,2-DIMETHYLHEPTYL)-1-HYDROXY-7,8,9,10-TETRAHYDRO-6,6,9- TRIMETHYL-6H-DIBENZO (b,d) PYRAN (DMHP).
(MDMA).
DIOXAPHETYL BUTYRATE.
ECGONINE. N-ETHYL-
-METHYL-3,4-(METHYLENEDIOXY)PHENETHYLAMINE ETHYLMETHYLTHIAMBUTENE.
ETICYCLIDINE *(PCE).
ETONITAZENE.
ETORPHINE.
ETOXERIDINE.
FENETYLLINE.
4-FLUORO-N-METHYLAMPHETAMINE. 1-(5-FLUOROPENTYL)-3-(2-IODOBENZOYL)INDOLE (AM-694)
FURETHIDINE.
HEROIN.
HYDROXYPETHIDINE.
ISOMETHADONE.
KETOBEMIDONE.

LEVOMETHORPHAN (excluding its stereoisomers).
LEVOPHENACYLMORPHAN.
LYSERGIC ACID.
LYSERGIDE.
(LSD)
MECLOQUALONE.
METAZOCINE.
METHAQUALONE.
METHCATHINONE.
5-METHOXY-
-METHYLTRYPTAMINE (5-MeO-AMT).
5-METHOXY-3,4-METHYLENEDIOXYAMPHETAMINE (MMDA).
4-METHOXY--METHYLPHENYLETHYLAMINE *(PMA).
2-(2-METHOXYPHENYL)-1-(1-PENTYLINDOL-3-YL)ETHANONE
METHYL (2
S, 4aR, 6aR, 7R, 9S, 10aS, 10bR)-9-ACETOXY-6a,10b-DIMETHYL-4,10-DIOXO-DODECAHYDRO-
2-(3-FURYL)-2H-NAPHTHO[2,1-c]PYRAN-7-CARBOXYLATE 4-METHYLAMINOREX.
METHYLDESORPHINE.
3,4-METHYLENEDIOXYAMPHETAMINE (MDA).
3,4-METHYLENEDIOXYPYROVALERONE (MDPV).
3-METHYLFENTANYL.
4-METHYLMETHCATHINONE *(MEPHEDRONE). N-
-[METHYL-3,4-(METHYLENEDIOXY)PHENETHYL]HYDROXYLAMINE N-METHYL-1-(3,4-METHYLENEDIOXYPHENYL)-2-BUTANAMINE (MBDB).
2-METHYL-3-MORPHOLINO-1, 1-DIPHENYLPROPANE CARBOXYLIC ACID (Moramide intermediate)
1-METHYL-4-PHENYL-4-PIPERIDINOL PROPIONATE 4-METHYLTHIOAMPHETAMINE. 3-METHYLTHIOFENTANYL.
METOPON.
(MPPP).
MITRAGYNA SPECIOSA.
MITRAGYNINE.
MORPHERIDINE. (1-(2-MORPHOLIN-4-YLETHYL)INDOL-3-YL)-NAPTHALEN-1-YLMETHANONE MUSCIMOL.

MYROPHINE.
NAPHTHOYLINDOLES
except when separately specified in these SchedulNAPHTHOYLPYRROLES except when separately specified in these Schedules. NAPHTHYLMETHYLINDENES except when separately specified in these Schedules.
NAPTHALEN-1-YL-(1-BUTYLINDOL-3-YL)METHANONE NICOCODINE.
NICODICODINE.
NICOMORPHINE.

NORACYMETHADOL.
NORLEVORPHANOL.
NORMORPHINE.
NORPIPANONE.
PARA-FLUOROFENTANYL. 1-PENTYL-3-(4-METHYL-1-NAPTHOYL)INDOLE.

1-PENTYL-3-(1-NAPHTHOYL)INDOLE PHENADOXONE.
PHENAMPROMIDE.
PHENAZOCINE.

PHENCYCLIDINE (PCP).
N-PHENETHYL-4-PIPERIDONE.
PHENOMORPHAN.
PHENYLACETYLINDOLES
except when separately specified in these Schedules.
1-PHENYLETHYL-4-PHENYL-4-PIPERIDINOL ACETATE PIMINODINE.
PROHEPTAZINE.
PROPERIDINE.

PSILOCYBINE. RACEMETHORPHAN.
RACEMORPHAN. ROLICYCLIDINE SALVIA DIVINORUM.

TENOCYCLIDINE *(TCP).
SYNTHETIC CANNABINOMIMETICS
except when separately specified in these Schedules. TETRAHYDROCANNABINOLS and their alkyl homologues except (a) when separately specified in this Schedule (b) when included in Schedule (c) in hemp seed oil, containing 50 mg/kg or less of tetrahydrocannabinols when labelled with a warning statement: Not for internal use; or Not to be taken; or (d) in products for purposes other than internal human use containing 50 mg/kg or less of tetrahydrocannabinols. THIOFENTANYL.
1-(3-TRIFLUOROMETHYLPHENYL)PIPERAZINE *(TFMPP).
TRIMEPERIDINE.
3,4,5-TRIMETHOXY--METHYLPHENYLETHYLAMINE *(TMA).
3,4,5-TRIMETHOXYPHENETHYLAMINE (mescaline) and other substances structurally derived from methoxy- phenylethylamine except(a) methoxyphenamine; or (b) when separately specified in this Schedule.
TRIMETHOXYPHENYL)-2-AMINOBUTANE.

[top]Penalties for schedule 9 drugs

[top]Cannabis


As stated above, cannabis has various penalties for possession depending on which state or territory you are in. In South Australia, The Australian Capital Territory and The Northern Territory, cannabis has been decriminalised, meaning that possession of small amounts of cannabis will not result in a criminal charge. New South Wales, Queensland, Victoria, Tasmania and Western Australia have laws that allow a criminal charge to be applied for any amount of cannabis possession, but it is unlikely that those laws would be enforced, especially on a first offense. Below is a table indicating the various laws and penalties within the states and territories of Australia in which cannabis has been decriminalised for minor cannabis offenses.

JurisdictionMaximum Amount of Cannabis AllowedFineAlternative to Fine
South Australia100 grams plant material, 20 grams resin, 1 plant$50-$150criminal conviction
Australian Capital Territory25 grams plant material, 2 plants$100Attend an alcohol and drug program
Northern Territory50 grams plant material, 10 grams resin, 1 gram oil, 10 grams seeds, 2 plants$200Debt to state - juveniles sent to assessment

Below is a table indicating the various laws and penalties within the states that cannabis has NOT been decriminalised. There is, however, a diversion program for people who engage in minor cannabis offenses.

JurisdictionMaximum Amount of Cannabis Allowed Allowed for Option of DiversionMaximum Number of CautionsDiversion Program
Tasmania50 grams3 in ten years1.Caution plus information 2.Brief Intervention 3.Assessment and Treatment
Victoria50 grams2Caution notice plus voluntary education program
New South Wales15 grams2Caution plus information and referral
Queensland50 grams1Mandatory assessment plus intervention
Western Australia10 grams1Caution plus cannabis intervention session

[top]Possession of Dangerous Drugs


The most common drug that people are charged for in Australia is cannabis, but it is an offense to be in possession of all schedule 9 drugs, and all schedule 8 drugs without sufficient identification.
The most common dangerous drugs that people would be in possession of are cocaine, heroin, lysergide (LSD), amphetamines and methyl-amphetamines (speed), mdma (ecstasy) and cannabis sativa (marijuana).
Possession of a dangerous drug is an offense, but the penalty depends on the amount and type of drug. As previously stated, the most common type of drug offense is for a small amount of marijuana (see table above in possession and penalties for cannabis), ranging to possession of heroin, for which the maximum penalty is 25 years imprisonment, although this would very rarely be enforced, depending on amounts and previous criminal convictions.
People charged with possession of small amounts of drugs would have the matter dealt with in a magistrate's court and it is unlikely that the person would receive a criminal conviction for a first time offense. Second and subsequent offenses of possession would most likely end in the person receiving a criminal conviction recorded.

[top]Production of Dangerous Drugs


People who produce dangerous drugs, most commonly heroin, cocaine, marijuana and amphetamines will receive a criminal conviction, but the penalties vary depending on the amounts. Examples of common penalties are shown in the table below:

DrugAmount of Drug producedPenalty
Heroin200 grams or more25 years imprisonment
Heroin2-200 grams25 years imprisonment EXCEPT when the person is drug dependent in which case the penalty is a maximum of 20 years imprisonment
HeroinUnder 2 grams20 years imprisonment
Cocaine200 grams or more25 years imprisonment
Cocaine2-200 grams25 years imprisonment EXCEPT when the person is drug dependent in which case the penalty is a maximum of 20 years imprisonment
CocaineUnder 2 grams20 years impronment
Marijuana500 grams or 100 plants20 years imprisonment
AmphetaminesOver 2 grams20 years imprisonment

[top]Trafficking Illicit Drugs


The most common schedule 9 drugs that incur penalties are shown in the table below. The two main categories for serious offenses are divided into trafficking marketable and commercial quantities of schedule 9 drugs into or out of Australia. The penalty for trafficking commercial quantities is a maximum of life imprisonment and the penalty for trafficking marketable quantities is a maximum of 25 years imprisonment. The following table indicates the amounts that are considered marketable and commercial amounts of schedule 9 drugs imported or exported to or from Australia.

DrugMarketable Quantity (grams)Commercial Quantity (kilograms)
Amphetamine2.00.75
Cannabis25,000100
Cannabis resin2050
Cocaine2.02.0
Heroin2.01.5
GHB2.01.0
LSD0.0020.002
Mescaline7.57.5
Methamphetamine2.00.75
MDMA0.50.5
Opium2020
Psilocine0.10.1
Psilocybine0.10.1

[top]References


1.National Cannabis Prevention and Information centre
http://ncpic.org.au/ncpic/publicatio...is-and-the-law
2.Department of Health and Ageing Therapeutic Goods Administration, Poisons Standard 2012, Anthony Gill.
3.The Law Handbook, Stan Winford.
http://www.lawhandbook.org.au/handbook/ch04s01s03.php
4.Therapeutic Goods Administration.
http://www.tga.gov.au/consumers/info...icines-cmi.htm
5.Ryan and Bosscher Lawyers.
http://www.aussielegal.com.au/inform...ailsID~817.htm

Created by out_there, 29-11-2012 at 03:36
Last edited by out_there, 17-02-2013 at 02:15
Last comment by Millie Platt on 30-10-2013 at 20:50
14 Comments, 20,263 Views

Share this on:
Page Tools


Posting Rules
You may not create new articles
You may not edit articles
You may not protect articles

You may not post comments
You may not post attachments
You may not edit your comments

BB code is On
Smilies are On
[IMG] code is On
HTML code is Off

Sitelinks: Information:

All times are GMT +1. The time now is 20:14.


Copyright: SIN Foundation 2003 - 2014, All rights reserved